[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteCall center
Email address
Condition
Treatment type
Investigational product
Phase
Sponsor
ClinicalTrials.gov identifier
Study number
Get answers to your questions about clinical trials.
This study has 2 parts: dose finding and dose confirmatory. In Part 1, the dose finding phase of the study, there will be 3 or more dosing levels to find out what dose of durvalumab administered as an infusion under the skin acts similarly to durvalumab administered into a vein. 24 participants with Non-Small Cell Lung Cancer will be enrolled for a 12 month treatment period and 3 months follow up In Part 2, the dose confirmation phase of the study, participants will receive the dose of durvalumab identified in Part 1 of the study. The goal of Part 2 will be to learn more about the way that the body processes durvalumab when administered as an infusion under the skin. Approximately 90 participants with Non-Small Cell Lung Cancer will be enrolled; additionally, up to 10 participants with Small Cell Lung Cancer (who will receive concurrent chemotherapy) will be enrolled for a 12 treatment period and a 3 month follow-up period.
You may be eligible to participate in the study if you meet the following criteria:
For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study Site